ArticleAmerican journal of translational research2024
Twelve Shugan Lidan Granules from traditional Chinese medicine can improve liver function in patients with postoperative hepatolithiasis by inhibiting the Hippo signaling pathway.
Article in American journal of translational research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHepatolithiasis (HL) is a complex liver and biliary disorder characterized by high rates of recurrence. This study aimed to evaluate the efficacy of Twelve Shugan Lidan Granules (TSLG), a compound herbal traditional Chinese formulation, in the treatment of HL, as well as to investigate its underlying mechanism.
methodsA retrospective analysis was conducted involving 157 patients diagnosed with HL, who were divided into two groups: the control group and the research group. In the control group, no treatment was given postoperatively, while in the research group, TSLG was orally administered three times a day postoperatively for two months. Both groups were followed up by telephone at 1 month, 2 months, and 3 months postoperatively. Liver function indicators were measured before and after surgery, and miRNA expression profiling was analyzed using high-throughput sequencing (HTS). Additionally, the expression levels of related proteins were assessed through western blots.
resultsPostoperative liver function indicators were significantly lower in the research group compared to the control group (P < 0.05). Additionally, 64 miRNAs were differentially expressed in HL patients. Further analysis of 64 miRNAs revealed their abnormal targeting of the Hippo signaling pathway. Further experimental results indicate that TAZ protein expression is elevated in HL patients, reflecting abnormal activation of the Hippo signaling pathway in these patients. TSLG treatment significantly reduced the expression of YAP, TAZ, and SREBP-2 proteins, while increasing the expression of p-YAP and p-TAZ proteins (all P < 0.05). Furthermore, TSLG inhibited the Extracellular Acidification Rate (ECAR) in LPS-induced WRL68 cells.
conclusionTSLG effectively improved postoperative liver function by downregulating sterol regulatory element-binding protein-2 (SREBP-2) and inhibiting the Hippo signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.